SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Novan, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Novan, Inc. NOVN concerning possible violations of federal securities laws.

During pre-market trading on January 27, 2017, the Company announced that Novan's two phase 3 pivotal clinical trials for its topical acne treatment had yielded different results. The Company revealed one trial showed statistical significance for all three co-primary endpoints and the other trial showed significance on only one. Since this announcement, shares of Novan have fallen from a close of $18.70 per share on January 26, 2017, to a close of $4.40 per share on January 30, 2017. To obtain additional information, go to:

http://zlk.9nl.com/novan-novn

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170131006328/en/